CLAIMS

What is claimed is:

1. A compound of formula (I) or a stereoisomer thereof or a pharmaceutically

acceptable salt thereof:

wherein

A represents a 3-7 membered cycloalkyl ring;

Ri represents H or alkyl;

R2 represents hydroxyalkyl, haloalkyl, an optionally substituted group selected from alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl, wherein the R2 is optionally substituted one or more times independently with a group selected from -CN, hydroxyl, -N02, -NRaRb, -ORc, alkyl, aryl, aralkyl, heterocyclyl, heteroaryl, ,-(CH2)nCOORd or -(CH2)nCON(R1)2;

R3 represents an optionally substituted group selected from aryl, heterocyclyl, heteroaryl, wherein the R3 is optionally substituted one or more times independently with a group selected from -CN, hydroxyl, halogen, alkyl, haloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, -CH2)nNRaRb, -ORc, - -SO2N(R 2, -COR5, -C(Re)=N-OH, (CH2)qCOORd

* represents hydrogen, hydroxyl, halogen, hydroxyalkyl, -N(Ri)2 or -NHCOORe;

Ra, in each occurrence, independently selected from hydrogen or alkyl;

Rb, in each occurrence, independently selected from alkyl,-COOR1? -CO-Ri or - S02-Re;

i each occurrence, independently selected from an optionally substituted group selected from alkyl, aryl, heteroaryl or heterocyclyl; each occurrence, independently selected from alkyl, aralkyl, -S02-Re,

-(CH2)pCOORd
Ri, in each occurrence, independently selected from hydrogen, alkyl, alkoxy,

haloalkyl, -CN, halogen, or -COORd;

Rd, in each occurrence, independently selected from hydrogen, an optionally substituted group selected from alkyl, aryl, heteroaryl or heterocyclyl; R5 represents alkyl or -N(R1)2;

m represents 0 or 1 ; and

n, p and q, in each occurrence, independently selected from 0, 1, 2, 3 or 4.

2. The com ound according to claim 1 having the formula (la):

wherein R3 is optionally substituted with one or more substituents selected independently from -CN, hydroxyl, halogen, alkyl, haloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, -(CH2)nNRaRb, -ORc, -S02Re, -SO2N(R 2, -COR5, -C(Re)=N-OH, -(CH2)qCOORd; , wherein Ra, Rb, Rc, Rd, Re, Ri, 5 and q are as defined in claim 1.

3. The compound according to claim 1 having the formula (lb):

wherein

Rx represents -CN, hydroxyl, -N02, -NRaRb, -ORc, alkyl, aryl, aralkyl,

heterocyclyl, heteroaryl, -(CH2)„COORd or -(CH2)„CON(R1)2, wherein Ra represents hydrogen or alkyl;

Rb represents alkyl -COOR^ -CO-Ri or -S02-Re, wherein R1 is as defined in claim 1; and R» represents an optionally substituted group selected from alkyl, aryl, heteroaryl or heterocyclyl;

Rc represents alkyl, aralkyl, -S02-Re, -(CH2)pCOORd,
wherein Rj is selected from hydrogen, -CN, halogen, alkyl, alkoxy, haloalkyl or -COORd, and wherein Rd represents hydrogen, an optionally substituted group selected from alkyl, aryl, heteroaryl or heterocyclyl;

n, p and q independently represents 0, 1, 2, 3 or 4;

R3 is selected from optionally substituted:

wherein R3 is optionally substituted with one or more substituents selected independently from -CN, hydroxyl, halogen, alkyl, haloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, -CH2) -ORc, -S02Re, -S02N(Ri)2, -COR5,

C(Re)=N-OH, -(CH2)qCOORd;
, and wherein Ra, Rb, Rc, Rd, Re, Ri, and q are as defined above.

The compound according to claim 3, wherein R4 represents hydrogen or hydroxyl.

The compound according to claim 1, wherein

R2 represents an optionally substituted alkyl, cycloalkyl, heteroaryl or heterocyclyl group, wherein one or more optional substituents are selected from -CN, hydroxyl, -N02; -NRaRb, -ORc, alkyl, aryl, aralkyl, heterocyclyl, heteroaryl, -(CH2)„COORd or -(CH2)nCON(R1)2, and wherein Ra, Rb, Rc, Rd, Rt and n are as defined in claim 1.

6. The compound according to claim 5, wherein R4 represents hydrogen or hydroxyl.

7. The compound according to claim 5, wherein R2 represents an optionally substituted heteroaryl group.

8. The compound according to claim 5, wherein R2 represents an optionally

substituted heterocyclyl group.

9. A compound selected from the group consisting of:

(S)- 1 -phenyl-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl)ethyl)cyclopropanecarboxamide hydrochloride;

(S)-N-methyl- 1 -phenyl-N-( 1 -phenyl -2-(pyrrolidin- yl] ethyl] cyclopentanecarboxamide hydrochloride;

(S)-N-methyl- 1 -phenyl-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl] ethyl] cyclohexane

carboxamide hydrochloride;

(S)-N-methyl- 1 -phenyl-N-( 1 -phenyl-2-(pyrrolidin- 1 yl] ethyl] cyclopropane

carboxamide hydrochloride;

(S)-N-methyl-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(quinolin-3 -yl)cyclopropane carboxamide hydrochloride;

(S)-l-phenyl-N-(l-phenyl-2-(pyrrolidin-l-yl) ethyl) cyclohexane carboxamide hydrochloride;

(S)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(pyridin-3 -yl)cyclopropane

carboxamide hydrochloride;

(S)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(quinolin-3 -yl)cyclopropane

carboxamide hydrochloride;

(S)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(pyridin-2-yl) cyclopropane

carboxamide hydrochloride;

N-((S)-2-((S)-3-hydroxypyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(quinolin-3 -yl)

cyclopropane carboxamide hydrochloride;

(S)-N-(3 -methyl- 1 -(pyrrolidin- 1 -yl) butan-2-yl)- 1 -(quinolin-3 -yl) cyclopropane carboxamide hydrochloride;

(S)- 1 -(benzo [d] oxazol-2-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(4-phenylthiazol-2-yl) cyclopropane carboxamide;

(S)- 1 -(benzo[d] [ 1 ,3]dioxol-5-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)- 1 -(benzo [d]thiazol-2-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)- 1 -(3 -cyanophenyl)-N-( 1 -phenyl-2 -(pyrrolidin- 1 -yl) ethyl) cyclopropane

carboxamide;

(S)-N-(2-(3 -(hydroxymethyl) azetidin- 1 -yl)- 1 -phenylethyl)- 1 -(quinolin-3 -yl)

cyclopropane carboxamide;

(S)- 1 -(4-(methylsulfonamido) phenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)- 1 -(3-(methylsulfonamido) phenyl)-N-(l -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)- 1 -(2-benzyl-2H-indazol-3-yl)-N-(l -phenyl-2-(pyrrolidin-l -yl) ethyl)

cyclopropane carboxamide;

(S)-N-(l-phenyl-2-(pyrrolidin-l-yl) ethyl)- 1-w-tolyl cyclopropane carboxamide hydrochloride;

(S)- 1 -(3 -hydroxyphenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide hydrochloride;

(S)-l-(3-(benzyloxy) phenyl)-N-(l-phenyl-2-(pyrrolidin-l-yl) ethyl) cyclopropane carboxamide hydrochloride;

(S)-N-(2-(3 -hydroxyazetidin- 1 -yl)- 1 -phenylethyl)- 1 -(quinolin-3-yl) cyclopropane carboxamide;

(S)- 1 -(3-(lH-tetrazol-5-yl) phenyl)-N-(l -phenyl-2-(pyrrolidin-l -yl) ethyl)

cyclopropane carboxamide;

(S)- 1 -(3 -cyanophenyl)-N-(3-methyl- 1 -(pyrrolidin- 1 -yl) butan-2-yl) cyclopropane carboxamide;

N-((S)-2-((S)-3 -hydroxy pyrrolidin- 1 -yl)- 1 -phenyl ethyl)- 1 -(3-(methyl

sulfonamido) phenyl) cyclopropane carboxamide;

(S)-4-(l-(l-phenyl-2-(pyrrolidin-l-yl) ethyl carbamoyl) cyclopropyl) phenyl

methane sulfonate hydrochloride;

4-(l -((S)-2-((S)-3-hydroxypyrrolidin- 1 -yl)- 1 -phenylethylcarbamoyl) cyclopropyl) phenyl methanesulfonate hydrochloride;

(5)-N-(3 -methyl- 1 -(pyrrolidin- 1-yl) butan-2-yl)-l -(3 -(methyl sulfonamido) phenyl) cyclopropane carboxamide;

3 -( 1 -((5)-2-((5)-3 -hydroxypyrrolidin- 1 -yl)- 1 -phenylethylcarbamoyl) cyclopropyl) phenyl methane sulfonate;

(S)-3-(l-(l -phenyl -2-(pyrrolidin-l-yl) ethyl carbamoyl) cyclopropyl) phenyl methane sulfonate;

N-((S)-2-((R)-3 -fluoropyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(quinolin-3 -yl)

cyclopropane carboxamide;

N-((S)-2-((R)-3 -hydroxypyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(quinolin-3 -yl)

cyclopropane carboxamide;

N-((S)-2-((R)-3 -hydroxypyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(3 -(methyl

sulfonamido) phenyl) cyclopropane carboxamide;

N-((S)-2-((S)-3 -fluoro pyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 - (quinolin-3 -yl)

cyclopropane carboxamide;

N-((S)-2-((S)-3 -hydroxypyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(3-isocyanophenyl) cyclopropane carboxamide;

N-((S)-2-((S)-3 -hydroxy pyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(quinoxalin-2-yl) cyclopropane carboxamide;

(S)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(quinoxalin-2-yl) cyclopropane carboxamide;

(S)-N-(l-phenyl-2-(pyrrolidin-l-yl) ethyl)- 1- (pyridin-4-yl) cyclopropane

carboxamide;

N-((S)-2-((S)-3-hydroxypyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(pyridin-4-yl)

cyclopropane carboxamide;

(S)- 1 -(4-(N,N-dimethylsulfamoyl)phenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)- 1 -(4-(methylsulfonamidomethyl) phenyl)-N-( 1 -phenyl -2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

N-((S)-2-((S)-3 -hydroxypyrrolidin- 1 -yl)- 1 -phenyl ethyl)- 1 -(4- (methyl

sulfonamide methyl) phenyl) cyclopropane carboxamide;

(S)- 1 -(3 -(methylsulfonamidomethyl) phenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 - yl)ethyl) cyclopropane carboxamide;

N-((S)-2-((S)-3-hydroxypyrrolidin- 1 -yl)- 1 -phenyl ethyl)- 1 -(3- (methylsulfonamidomethyl) phenyl) cyclopropane carboxamide;

N-((S)-2-((S)-3-(dimethylamino) pyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(3- (methylsulfonamido) phenyl) cyclopropanecarboxamide;

N-((S)-2-((S)-3 -(dimethylamino) pyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(quinolin-2-yl) cyclopropane carboxamide;

(S)- 1 -(4-(methylsulfonyl) phenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl)ethyl)

cyclopropane carboxamide;

(S)-l-(2-(N, N-dimethyl sulfamoyl) phenyl)-N-(l-phenyl-2-(pyrrolidin-l-yl)ethyl) cyclopropane carboxamide;

(S)- 1 -(3 -(methylsulfonyl) phenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl)

cyclopropane carboxamide hydrochloride;

(S)- 1 -(3 -methoxyphenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)-l-(2,2-dioxido-l,3-dihydrobenzo[c]isothiazol-5-yl)-N-(l-phenyl-2-(pyrrolidin- l-yl)ethyl) cyclopropane carboxamide;

(S)- 1 -(4-methoxyphenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)-l-(2-oxo-l,2-dihydroquinolin-6-yl)-N- (l-phenyl-2- (pyrrolidin- 1-yl) ethyl) cyclopropane carboxamide;

(S)- 1 -(4-chlorophenyl)-N-(l -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane

carboxamide; (S)-l-(4-chloro-3 -(methyl sulfonamido) phenyl)-N-(l- phenyl-2 -(pyrrolidin- 1-yl) ethyl) cyclopropane carboxamide;

rt-butyl (S)-l-((S)-2-(l-(3- (methylsulfonamido) phenyl) cyclopropane

carboxamido)-2-phenylethyl) pyrrolidin-3 -ylcarbamate ;

N-((S)-2-((S)-3 -(methyl amino) pyrrolidin- 1 -yl)- 1 -phenylethyl)- 1 -(3- (methylsulfonamido) phenyl) cyclopropane carboxamide;

N-((S)-2-((S)-3 -amino pyrrolidin- l-yl)-l -phenyl ethyl)- 1- (3 -(methyl sulfonamido) phenyl) cyclopropane carboxamide 2,2,2-trifluoroacetate;

l-(2,2-Dioxo-2,3-dihydro-2-benzo[ 1,2,3] oxathiazol 5-yl)- cyclopropane

carboxylic acid (l-phenyl-2-pyrrolidin-l-yl-ethyl)-amide;

l-(3-Dimethylsulfamoyl-phenyl)-cyclopropane carboxylic acid (l-phenyl-2- pyrrolidin- 1 -yl-ethyl)-amide;

l-(4-Sulfamoyl-phenyl)-cyclopropane carboxylic acid (l-phenyl-2- pyrrolidin- 1- yl-ethyl)-amide;

1 -(3- Acetyl -4-hydroxyphenyl)-cyclopropane carboxylic acid (l-phenyl-2- pyrrolidin- 1 -yl-ethyl)-amide;

1 -(2-Oxo-2,3 -dihydro-benzooxazol-5-yl)-cyclopropane carboxylic acid (1-phenyl- 2-pyrrolidin- 1 -yl-ethyl)-amide;

l-(3-Methanesulfonylamino-phenyl)-cyclopropane carboxylic acid (l-benzyl-2- pyrrolidin- 1 -yl-ethyl)-amide;

l-(3-Methanesulfonylamino-phenyl)-cyclopropane carboxylic acid (l-pyridin-3-yl- 2-pyrrolidin- 1 -yl-ethyl)-amide;

(S)-N-( 1 -cyclohexyl-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(3 -(methylsulfonamido)phenyl) cyclopropane carboxamide;

(S)-N-(4-methyl- 1 -(pyrrolidin- 1 -yl)pentan-2-yl)- 1 -(3-(methylsulfonamido) phenyl) cyclopropanecarboxamide ;

(R)-N-( 1 -(3-(benzyloxy)phenyl)-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(3 -(methyl

sulfonamido) phenyl)cyclopropanecarboxamide;

(R)-N-( 1 -(3 -hydroxyphenyl)-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(3 -(methylsulfonamido) phenyl) cyclopropanecarboxamide;

(R)-N-( 1 -(3 -methoxyphenyl)-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(3 -(methylsulfonamido) phenyl) cyclopropanecarboxamide;

l-(3-Methanesulfonylamino-4-methoxy-phenyl)-cyclopropane carboxylic acid (1- phenyl-2 -pyrrolidin- 1 -yl-ethyl)-amide;

l-(3-Methyl-benzo[d] isoxazol-5-yl)-cyclopropane carboxylic acid (l-phenyl-2- pyrrolidin- 1 -yl-ethyl)-amide;

l-(6-Ethoxy-pyridin-2-yl)-cyclopropane carboxylic acid (l-phenyl-2-pyrrolidin-l- yl-ethyl)-amide;

l-(4-Methanesulfonylamino-3-methyl-phenyl)-cyclopropanecarboxylic acid (1- phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

l-(3-Methanesulfonylamino-4-methyl-phenyl)-cyclopropane carboxylic acid (1- phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

1 -(3-Formylamino-4-hydroxy-phenyl)-cyclopropanecarboxylic acid (1 -phenyl-2- pyrrolidin- 1 -yl-ethyl)-amide;

l-(4-Fluoro-3-methanesulfonylamino-phenyl)-cyclopropane carboxylic acid (1- phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

l-(2,2-Dioxo-2,3-dihydro-lH-2-benzo[c] isothiazol-6-yl)-cyclopropane carboxylic acid ( 1 -phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

1 -Benzooxazol-6-yl-cyclopropanecarboxylic acid ( 1 -phenyl-2-pyrrolidin- 1 -yl- ethyl)-amide;

3 - [ 1 -( 1 -Phenyl -2-pyrrolidin- 1 -yl-ethylcarbamoyl)-cyclopropyl]-benzamide;

1 -(2,4-Difluoro-5-methanesulfonylamino-phenyl)-cyclopropane carboxylic acid

(1 -phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

l-[4-Hydroxy-3-(l-hydroxyimino-ethyl)-phenyl]-cyclo propane carboxylic acid (1- phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

l-(2-Oxo-2,3-dihydro-lH-benzoimidazol-5-yl)-cyclo propane carboxylic acid (1- phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

l-(l-Methyl-lH-benzotriazol-5-yl) cyclopropane carboxylic acid (l-phenyl-2- pyrrolidin- 1 -yl-ethyl)-amide;

l-(2-Oxo-l,2-dihydro-quinolin-7-yl)-cyclopropane carboxylic acid (l-phenyl-2- pyrrolidin- 1 -yl-ethyl)-amide;

{ 3 - [ 1 -( 1 -Phenyl-2-pyrrolidin- 1 -yl-ethylcarbamoyl)-cyclopropyl] -phenoxy } -acetic acid;

4- [ 1 -( 1 -Phenyl -2-pyrrolidin- 1 -yl-ethylcarbamoyl)-cyclopropyl] -benzamide;

1 -(2,2-Dioxo- 1 ,2-dihydro-216-benzo[c] [ 1 ,2]thiazin-7-yl)-cyclopropane carboxylic acid ( 1 -phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

l-(lH-Benzoimidazol-5-yl)-cyclopropanecarboxylic acid (l-phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide;

l-(4-Fluoro-3-methanesulfonylamino-phenyl)-cyclopropane carboxylic acid (1- phenyl-2-pyrrolidin- 1 -yl-ethyl)-amide hydrochloride;

1 -(4-Fluoro-3-methanesulfonylamino-phenyl)-cyclopropanecarboxylic acid [2-(3- hydroxy-pyrrolidin- 1 -yl)- 1 -phenyl-ethyl] -amide;

{4- [ 1 -( 1 -Phenyl-2-pyrrolidin- 1 -yl-ethylcarbamoyl)-cyclopropyl] -phenoxy} -acetic acid;

(S)- 1 -(6-(methylsulfonamido) pyridin-3 -yl)-N-( 1 -phenyl -2-(pyrrolidin- 1 -yl)ethyl) cyclopropanecarboxamide ;

(S)- 1 -(2,2-dioxido- 1 H-benzo[c] [ 1 ,2]thiazin-6-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 - yl)ethyl) cyclopropanecarboxamide ;

(S)- 1 -( 1 H-indazol-5-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl)

cyclopropanecarboxamide;

(S)- 1 -(benzo[d]isoxazol-5-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl) cyclopropane carboxamide;

(S)-3-(l-(l -phenyl-2-(pyrrolidin- 1 -yl) ethylcarbamoyl)cyclopropyl)benzoic acid;

(S)-N-( 1 -(3 -methoxyphenyl)-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(2-oxo-2,3 - dihydrobenzo[d]oxazol-5-yl)cyclopropanecarboxamide;

N-((S)-2-((S)-3-hydroxypyrrolidin-l-yl)-l-phenylethyl)-l-(2-oxo-2,3- dihydrobenzo [d] oxazol-5 -yl)cyclopropanecarboxamide ;

(S)-tert-butyl 2-(2-oxo-5-(l-(l-phenyl-2-(pyrrolidin-l-yl)

ethylcarbamoyl)cyclopropyl) benzo [d] oxazol-3 (2H)-yl)acetate ;

(S)-2-(2-oxo-5-( 1 -(1 -phenyl-2-(pyrrolidin- 1 -yl)

ethylcarbamoyl)cyclopropyl)benzo[d] oxazol-3 (2H)-yl)acetic acid hydrochloride;

(S)-N-(l -cyclohexyl-2-(pyrrolidin-l -yl)ethyl)- 1 -(2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)cyclopropanecarboxamide;

(S)- 1 -(3 -methyl- 1 H-indazol-5-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl)

ethyl)cyclopropane carboxamide;

(S)-N-( 1 -(3 -methoxyphenyl)-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(3 -methyl- 1 H-indazol-5- yl)cyclopropanecarboxamide ;

(S)-4-(l-(l-phenyl-2-(pyrrolidin-l-yl) ethyl carbamoyl) cyclopropyl)benzoic acid; (S)-l-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-N-(l-phenyl-2- (pyrrolidin- 1 -yl)ethyl)cyclopropanecarboxamide;

N-((S)- 1 -cyclohexyl-2-((S)-3 -hydroxypyrrolidin- 1 -yl) ethyl)- 1 -(2-oxo-2,3 -dihydro benzo[d]oxazol-5-yl)cyclopropanecarboxamide;

(S)-N-(l -(3-cyanophenyl)-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)cyclopropanecarboxamide;

(S)-3 -( 1 -( 1 -(2-oxo-2,3 -dihydrobenzo [d] oxazol-5 -yl)cyclopropanecarboxamido)-2- (pyrrolidin- 1 -yl)ethyl)benzamide;

(S)-2-(3 -( 1 -( 1 -(3-(methylsulfonamido)phenyl)cyclopropanecarboxamido)-2- (pyrrolidin- 1 -yl)ethyl)phenoxy)acetic acid;

(S)-N-( 1 -(3 -(benzyloxy)phenyl)-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(2-oxo-2,3 - dihydrobenzo [d] oxazol-5-yl)cyclopropanecarboxamide;

(S)-N-(l -(3-hydroxyphenyl)-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)cyclopropanecarboxamide;

(S)- 1 -(4-cyanophenyl)-N-( 1 -phenyl-2-(pyrrolidin- 1 - yl)ethyl)cyclopropanecarboxamide;

(S)-3-(l -(1 -(2-oxo-2,3-dihydrobenzo[d]oxazol-5- yl) cyclopropanecarboxamido)- 2-(pyrrolidin-l-yl) ethyl)phenyl methanesulfonate 2,2,2-trifluoroacetate;

(S)-N-(l-(3-(2H-tetrazol-5-yl) phenyl)-2-(pyrrolidin-l-yl)ethyl)-l-(2-oxo-2,3- dihydro benzo [d] oxazol-5 -yl)cyclopropanecarboxamide;

N-((S)-2-((S)-3 -hydroxypyrrolidin- 1 -yl)- 1 -(3 -methoxyplienyl)etl yl)- 1 -(2-oxo-2,3 - dihydro benzo[d]oxazol-5-yl)cyclopropanecarboxamide;

(S)-methyl 4-((5-(l -(1 -(3-hydroxyphenyl)-2-(pyrrolidin-l - yl)ethylcarbamoyl)cyclopropyl)-2-oxobenzo [d] oxazol-3 (2H)- yl)methyl)benzoate;

(S)-methyl 3 -((5 -( 1 -( 1 -(3 -hydroxyphenyl)-2-(pyrrolidin- 1 - yl)ethylcarbamoyl)cyclopropyl)-2-oxobenzo[d]oxazol-3(2H)- yl)methyl)benzoate;

N-((S)- 1 -(3-hydroxyphenyl)-2-((S)-3-hydroxypyrrolidin- 1 -yl)ethyl)- 1 -(2-oxo-2,3- dihydro benzo [d] oxazol-5 -yl)cyclopropanecarboxamide ;

N-((S)-1 -(3 -hydroxyphenyl)-2-((S)-3 -hydroxypyrrolidin- 1-yl) ethyl)- l-(2-oxo-2,3- dihydro benzo [d] oxazol-5 -yl)cyclopropanecarboxamide;

(S)-N-( 1 -(3 -aminophenyl)-2-(pyrrolidin- 1 -yl) ethyl)- 1 -(2-oxo-2,3 - dihydrobenzo [d] oxazol-5-yl)cyclopropanecarboxamide;

(S)- 1 -(2-oxoindolin-6-yl)-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethyl)cy

clopropanecarboxamide;

(S)-N-(l-(3-(3-cyanobenzyloxy) phenyl)-2-(pyrrolidin-l-yl)ethyl)-l-(2-oxo-2,3- dihydro benzo [d] oxazol-5 -yl)cyclopropanecarboxamide ;

(S)-N-( 1 -(3 -(4-cyanobenzyloxy) phenyl)-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(2-oxo-2,3 - dihydro benzo[d]oxazol-5-yl)cyclopropanecarboxamide;

l-(2-Oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-N-(2-(pyrrolidin-l-yl)-l-(tetrahydro- 2H-pyran-4-yl)ethyl)cyclopropanecarboxamide;

N-( 1 -( 1 -benzyl- 1 H-pyrazol-4-yl)-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(2-oxo-2,3 - dihydrobenzo [d] oxazol-5 -yl)cyclopropane carboxamide;

(S)-methyl-3 -(2-oxo-5 -( 1 -( 1 -phenyl-2-(pyrrolidin- 1 -yl) ethylcarbamoyl)

cyclopropyl) benzo [d] oxazol-3 (2H)-yl)methyl)benzoate ;

(S)-N-( 1 -(3 -(methylsulfonamido)phenyl)-2-(pyrrolidin- 1 -yl)ethyl)- 1 -(2-oxo-2,3 - dihydrobenzo[d]oxazol-5-yl)cyclopropanecarboxamide; and

(S)-N-methyl- 1 -phenyl-N-( 1 -phenyl-2-(pyrrolidin- 1 -yl] ethyl] cyclobutane

carboxamide hydrochloride;

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising one or more compounds according to claim 1 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising one or more compounds according to claim 9 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

12. A compound according to claim 1, which is kappa (κ) opioid receptor (KOR) agonist.

13. A compound according to claim 9, which is kappa (J) opioid receptor (KOR) agonist.

14. A method of binding an opioid receptor in a patient, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 , or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

15. The method according to claim 14, wherein the compound binds κ opioid receptor site.

16. The method according to claim 15, wherein the κ opioid receptor site is located in the central nervous system.

17. The method according to claim 16, wherein the κ opioid receptor site is located peripherally to the central nervous system.

18. A method of treating gastrointestinal dysfunction in a patient comprising

administering to the patient a therapeutically effective amount of a compound according to claim 1 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

19. A method of treating ileus in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

20. A method of treating pain in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

21. The method according to claim 20, wherein the pain is selected from the group consisting of acute pain and chronic pain.

22. The method according to claim 21, wherein the pain is acute pain.

23. The method according to claim 21, wherein the pain is chronic pain.

24. The method according to claim 20, wherein the pain is selected from the group consisting of nociceptive pain, inflammatory pain, visceral pain, somatic pain, neuralgia, neuropathic pain, pain caused by autoimmune diseases (AIDS), pain caused by cancer, phantom pain, psychogenic pain, pain resulting from

hyperalgesia, pain caused by rheumatoid arthritis, migraine and allodynia.

25. A method of binding an opioid receptor in a patient, comprising administering to the patient a therapeutically effective amount of a compound according to claim 9, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

26. The method according to claim 25, wherein the compound binds κ opioid receptor site.

27. The method according to claim 26, wherein the κ opioid receptor site is located in the central nervous system.

28. The method according to claim 27, wherein the κ opioid receptor site is located peripherally to the central nervous system.

29. A method of treating gastrointestinal dysfunction in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 9 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

30. A method of treating ileus in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 9 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

31. A method of treating pain in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 9 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

32. The method according to claim 31 , wherein the pain is selected from the group consisting of acute pain and chronic pain.

33. The method according to claim 32, wherein the pain is acute pain.

34. The method according to claim 32, wherein the pain is chronic pain.

35. The method according to claim 31, wherein the pain is selected from the group consisting of nociceptive pain, inflammatory pain, visceral pain, somatic pain, neuralgia, neuropathic pain, pain caused by autoimmune diseases (AIDS), pain caused by cancer, phantom pain, psychogenic pain, pain resulting from hyperalgesia, pain caused by rheumatoid arthritis, migraine and allodynia.